Pharma BD Deal Intelligence

AstraZeneca plc / Aspen Global Inc. (Aspen Pharmacare)

2016 · Asset Purchase · $770M · Complete

Announcement Sentiment

Positive

AstraZeneca sold ex-U.S. commercialization rights for its seven-product anaesthetics portfolio to Aspen Global for $520M upfront plus up to $250M in product sales-related milestones, plus double-digit trademark royalties. Portfolio comprised Diprivan (general anaesthesia), EMLA (topical), and five local anaesthetics. Completed September 2016. Part of AstraZeneca's strategy to divest non-core mature assets.

Did it work? Outcome assessment

Strategic verdict

Achieved Stated Rationale

Financial impact

Accretive

Pipeline outcome

Assets Advanced

Assessment window: 5yr post-close.

Key facts

Announced Jun 08, 2016
Closed Sep 01, 2016
Deal value $770M
Deal type Asset Purchase
Therapeutic area General and local anaesthesia
Indications General and local anaesthesia
Key assets Anaesthetics portfolio: Diprivan, EMLA, Carbocaine, Citanest, Marcaine, Naropin, Xylocaine
Mechanism Anaesthetic agents (multiple classes)

See the full interactive analysis, sources & comparables →

← Browse all deals · How we score deals